SCHEMBL11919941

SCHEMBL11919941

Cc1ccc(-c2noc(C3(Sc4nnc(-c5ccncc5)n4-c4ccccc4C)CCCC3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 6/20 0.47
ALDH1A1 P00352 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
ALOX15 P16050 1/20 0.47
MAPT P10636 6/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
HTT P42858 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
GAA P10253 1/20 0.44
TP53 P04637 4/20 0.43
LMNA P02545 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TNKS O95271 3/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
SULT2A1 Q06520 1/20 0.42
NR5A1 Q13285 1/20 0.42
AXIN2 Q9Y2T1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11919940 0.98 TNKS2 (0.47) TNKS2ALDH1A1NPSR1ALOX15MAPT
SCHEMBL11919938 0.96 TNKS2 (0.48) TNKS2ALDH1A1NPSR1ALOX15MAPT
SCHEMBL11919960 0.93 TNKS2 (0.45) TNKS2ALDH1A1NPSR1ALOX15MAPT
SCHEMBL13047151 0.84 NPSR1 (0.55) TNKS2ALDH1A1NPSR1MAPTSMN1; SMN2
SCHEMBL11919953 0.83 TNKS2 (0.64) TNKS2ALDH1A1NPSR1MAPTSMN1; SMN2
SCHEMBL11919952 0.81 TNKS2 (0.64) TNKS2ALDH1A1NPSR1MAPTSMN1; SMN2
SCHEMBL13049096 0.80 NPSR1 (0.57) TNKS2ALDH1A1NPSR1MAPTSMN1; SMN2
SCHEMBL11919951 0.79 TNKS2 (0.66) TNKS2ALDH1A1NPSR1MAPTSMN1; SMN2
SCHEMBL11919939 0.78 TNKS2 (0.49) TNKS2ALDH1A1NPSR1ALOX15MAPT
SCHEMBL11919905 0.77 NPSR1 (0.77) TNKS2ALDH1A1NPSR1ALOX15MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors WNT1, AXIN2, WNT3 TNKS2 1460/4885ALDH1A1 1296/4885NPSR1 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.